New hope for aggressive breast cancer: drug duo plus chemo shows promise
NCT ID NCT05227664
First seen Mar 22, 2026 · Last updated May 10, 2026 · Updated 8 times
Summary
This study tests whether adding two experimental drugs (AK117 and AK112) to standard chemotherapy can shrink tumors in people with advanced triple-negative breast cancer that hasn't been treated before. About 120 participants will receive the combination and be monitored for response and side effects. The goal is to see if this approach improves outcomes compared to chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, China
-
Xiangyang Central Hospital
Xiangyang, China
Conditions
Explore the condition pages connected to this study.